Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of inflammatory diseases
3.2.1.2 Technological advancements in drug development
3.2.1.3 Rising prevalence of cancer
3.2.1.4 Increasing awareness and diagnosis
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse effects and safety concerns
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Regulatory landscape
3.6 Technological landscape
3.6.1 Core technologies
3.6.2 Adjacent technologies
3.7 Pricing analysis, 2023
3.7.1 By region
3.7.2 By key player
3.8 Future market trends
3.9 Porter’s analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Selective cox 1 inhibitor
5.3 Non-selective Cox 1 inhibitor
Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Inflammatory diseases
6.3 Gastrointestinal toxicity
6.4 Cancer chemoprevention
6.5 Other applications
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacy
7.3 Retail pharmacy
7.4 Online pharmacy
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AbbVie Inc.
9.2 Alembic Limited
9.3 Aurobindo Pharma Limited
9.4 Boehringer Ingelheim International GmbH
9.5 Bayer AG
9.6 Cipla Limited
9.7 Hikma Pharmaceuticals PLC
9.8 Johnson & Johnson
9.9 Novartis AG
9.10 Pfizer Inc.
9.11 Sabinsa
9.12 Teva Pharmaceutical Industries Ltd
9.13 Torrent Pharmaceuticals Limited
9.14 Viatris Inc.
9.15 Zydus Lifesciences Limited
